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ABSTRAK
Tujuan: menganalisis terjadinya penyakit paru obstruktif kronik dan hubungannya dengan polimorfisme 
gen TNFa pada posisi -308 dan -238 dan gen LTα pada posisi +252. Metode: penelitian potong lintang dengan 
membandingkan genetik sekelompok orang pasien PPOK dan sekelompok orang yang tidak memiliki PPOK 
dengan riwayat merokok yang sama. Penelitian dilakukan mulai Januari 2011 sampai Maret 2012 di Poliklinik 
Paru RS Adam Malik, RS. Pirngadi, RS. Tembakau Deli, RS. Siti Hajar Medan dan beberapa Puskesmas di 
kota Medan. Pemeriksaan faal paru dilakukan dengan menggunakan spirometri dan analisis gen dengan 
teknik PCR-RFLP. Hasil: 227 orang memenuhi kriteria inklusi dan dilakukan penyetaraan umur. Riwayat 
merokok sebanyak 186 orang (93 orang sebagai kelompok kasus dan 93 orang sebagai kelompok kontrol). 
Untuk polimorfisme -308G/A gen TNFα dijumpai genotip GA dan AA sebanyak 18 pada subyek PPOK dan 33 
pada subyek non-PPOK. Sedangkan untuk genotip GG sebanyak 75 pada subyek dengan PPOK dan 60 pada 
non-PPOK, rasio odds 0,436 (95% IK 0,224 - 0,850; p=0,014). Polimorfisme -238G/A gen TNFα dijumpai 
genotip GA dan AA sebanyak 8 pada PPOK dan 4 pada non-PPOK. Sedangkan untuk genotip GG sebanyak 85 
pada PPOK dan 89 pada non-PPOK dengan rasio odds 2,094 (95% CI 0,608 - 7,211; p=0,241). Polimorfisme 
+252A/Ggen LTα dijumpai genotip GA dan GG sebanyak 55 pada PPOK dan 60 pada non-PPOK. Sedangkan 
untuk genotip AA sebanyak 38 pada PPOK dan 33 pada non-PPOK, rasio odds 1,256 (95% CI 0,694 – 2,272; 
p=0,450). Kesimpulan: polimorfisme gen TNFα pada posisi -308 terbukti sebagai faktor protektif terjadinya 
PPOK. Polimorfisme gen TNFα pada posisi -238 dan gen LTα pada posisi +252 tidak terbukti berhubungan 
dengan kejadian PPOK.
Kata kunci: penyakit paru obstruktif kronik, gen TNFα, gen LTα, polimorfisme.
ABSTRACT
Aim: to analyze the occurrence of chronic obstructive pulmonary disease (COPD) and its association with 
the polymorphisms of -308G/A, -238G/A of TNFα gene and +252A/G LTα gene polymorphism in smokers. 
Methods: cross-sectional study, comparing the genetic group of people who have COPD and who do not have 
COPD with the same smoking history. The study was conducted from January 2011 to March 2012 at several 
health centers; such as Adam Malik Hospital, Pirngadi Hospital, Tembakau Deli Hospital, Siti Hajar Hospital in 
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INTRODUCTION
Chronic Obstructive Pulmonary Disease 
(COPD) will be the cause of illness and death 
worldwide. Based on WHO estimation, COPD 
will become the third leading cause of death 
in 2020. The causes are increasing number of 
smokers, fewer deaths from other diseases (heart 
and infection), and increasing life expectancy.1 
Smoking is an important risk factor in the decline 
in lung function, but only 10-20% of chronic 
heavy smokers will suffer from COPD. This 
indicates that different susceptibility to damage 
due to smoking is likely related to genetic factors. 
Zhai2 found a strong influence between 
genetics structure to the ratio of FEV1 value 
obtained from patients compared to the healthy 
non-smoker persons; moreover, the genetics 
itself is also influenced by smoking habit. 
Smoking habits will affect gene expression 
in lung function, but the mechanisms on how 
this happens in susceptible person are still not 
understood yet. COPD has been recently defined 
as a complex disorder derived from interactions 
of several genetics and environmental factors. 
The development of genetic variant identification 
technique is expected to reveal a new mechanism 
on COPD pathogenesis.  A copy number variation 
(CNV) enables us to describe differences in gene 
sequence as well as the structures, which may 
contribute in explaining susceptibility of a person 
to COPD. A good understanding on genetic 
variation, gene expression and its regulation will 
allow us to reveal novel mechanism of COPD 
that can be applied in term of treatment.
Polymorphism or Single Nucleotide 
Polymorphism (SNP) is a nucleotide sequence 
variation or change in one of the nucleotide bases 
in the gene. TNFα gene polymorphism -238 G/A 
and -308G/A is the change in the nucleotide bases 
guanine into adenine at position of -238 and -308. 
LTα gene polymorphism +252 A/G is a change 
in the nucleotide bases adenine into guanine at 
position of +252. These changes will result in 
changes in transcription process that affect the 
protein production of TNFα and LTα. Based 
on the position, polymorphisms affect only the 
velocity of protein synthesis.2-7
S t u d i e s  o n  T N F α  a n d  LT α  g e n e 
polymorphisms in association with COPD 
patients in Indonesian population have not been 
performed. Therefore, our study was aimed to 
analyze the occurrence of COPD based on the 
role of TNFa gene polymorphisms at position of 
-308 and -238 and LTα gene at position of+252.
METHODS
Our study was a cross-sectional study 
comparing the genetics of a group of people 
who had suffered from COPD (case group) and 
a group of people who had not sufferred from 
COPD (control group) with the same smoking 
history. The study was conducted between 
January 2011 and March 2012 in several 
locations such as Lung Clinic at H.Adam Malik 
Hospital, Pirngadi Hospital, Tembakau Deli 
Hospital, Siti Hajar Hospital and several health 
Medan and several health centers in the city of Medan. Examination of lung function was done using spirometry 
and the existence of genetic polymorhisms in the TNFα and LTα gene was performed using polymerase chain 
reaction-restriction fragment length polymorphisms (PCR-RFLP). Results: of the total of 227 samples that met 
inclusion criteria and after equalizing the age and history of smoking, 186 subjects were enrolled, of which, 93 
people as COPD group and 93 people as non-COPD group. Analysis of the association between the -308G/A 
polymorphism with the COPD revealed the odds ratio (OR) 0.436 (95% CI 0.224-0.850, p=0.014). Polymorphism 
at -238G/A of the TNFα gene showed the OR 2.094 (95% CI 0.608 - 7.211, p=0.241). Polymorphism at +252A/G 
LTα gene showed OR 1.256 (95% CI 0.694 - 2.272; p=0.450). The findings indicated that polymorphism at 
-308G showed a protective factor whereas the -238G/A of the TNFα and +252A/G  of the LTα genes did not 
show any significant association with the COPD. Conclusion: polymorphism -308 TNFα gene shown to be a 
protective factor for the occurrence of COPD. Polymorphism -238 TNFα gene and +252 LTα gene did not show 
any significant association with COPD.
Key words: chronic obstructive pulmonary disease, TNFα gene, LTα gene, polymorphism.
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centers in Medan. Institutional Review Board 
(IRB) from Ethic Committee at Medical Faculty 
University Of North Sumatera had issued their 
approval on 8 Februari 2011 (No.47/KOMET/
FK USU/2011, informed Consent (IC) written 
was required). The target population in this 
study was patients suffering from COPD; while 
the accessible population was COPD patients 
seeking treatment at study site. There were 
two groups in our study, i.e. the case group and 
control group.  The case group included patients 
with COPD who fulfilled the inclusion criteria 
and exclusion criteria. The inclusion criteria 
were: Patients with COPD who had already 
been confirmed by spirometry test (VEP1/KVP 
<70% in 15 minutes after given two sprays of 
salbutamol in metered dose inhaler with spacer), 
the severity of illness was graded according to 
GOLD classification (mild  to very heavy), age 
≥40 years, male, current smokers or ex-smokers 
with smoking history of >200 Brinkman index 
(IB). The exclusion criteria were patients with 
asthma, pulmonary tuberculosis or other lung 
diseases.
The control group were adult smokers 
without COPD who met inclusion and exclusion 
criteria. The inclusion criteria were those with 
normal pulmonary function, which have been 
confirmed by spirometry test (VEP1/KVP 
>70%), age ≥40 years, male, active smokers 
or ex-smokers with smoking history of >200 
IB. The exclusion criteria were patients with 
lung diseases such as tuberculosis, chronic 
bronchitis or other lung diseases, and history of 
family member with COPD. Venous blood was 
withdrawn from the median cubital vein by using 
a 3-cc syringe, and the blood was collected for 
further DNA gene isolation analyzed by using 
PCR-RFLP method.
PCR-RFLP of -308 TNFα Gene
The TNFα-308 genotype (rs1800629) was 
analyzed with the PCR-RFLP method (Polymerase 
Chain Reaction-Restriction Fragment Length 
Polymorphism) by using primers for the 
PCR gene amplification using ATF-3 primer 
(5’-GTTCCTTGG AAGCCAAGACT-3’) and 
ATR-1 (5’-GTCAGGGGATGTGGCGTCT-3’ 
in the first reaction stage and ATF-2 primer 
(5’-TGGAGGCAATAGGTTTTGAGGGCCAT 
-3’ and ATR-2 (5’-TCATCTGGAGGAAGCG 
GTA-3’) for the second PCR reaction. PCR was 
performed using a Perkin Elmer PCR model 
9700 machine. PCR reaction volume was 50 
μL containing the following ingredients: 10 X 
buffer solution (5 μL), 50 mM MgCl 2 (1.5 μL), 
10 mM dNTPs (1 μL), ATF-3 primer 40 pmol/
μL (0.5 μL), the primary ATR-1 40 pmol/mL 
(0.5 μL), the isolated DNA samples (5 μL) and 
1 unit of Taq polymerase enzyme. PCR cycle 
condition in the first stage reaction in TNF 
gene fragment amplification was 940C for 30 
sec, 580C for 30 sec and 720C for 1.5 min in 
30 cycles. At the beginning of the reaction, an 
additional denaturation time 940C for 5 minutes 
was allocated and at the end of the reaction, there 
was  additional elongation time for denaturation 
at 720C for 5 minutes. PCR cycle condition in 
the second stage TNF gene amplification reaction 
was 940C for 30 sec, 610C for 30 sec and 720C 
for 1 min as many as 40 cycles with  additional 
denaturation time at early reaction of 940C  for 
5 min and additional elongation time of 720C 
for 5 minutes. Composition of the solution in 
the second phase of the PCR reaction was equal 
to the first stage of the reaction, except the used 
primers were ATF-2 and ATR-2 with DNA, 
which were the products of the first stage PCR. 
They were used as the template with the amount 
of 1μL.
About 5 μL product of the PCR second phase 
from each sample was mixed with 2 μL loading 
buffer and then inserted into the gel wells. In 
one line of wells, one well was included to place 
the marker DNA. Electrophoresis was run at a 
voltage of 100 volts (~ 50 mA) for approximately 
40 minutes. Electrophoresis result was seen 
under ultra violet light (UV). Positive TNFα gene 
PCR result was indicated by the presence of DNA 
band with size 231 pb. To determine whether the 
samples brought nucleotide A and/or nucleotide 
G at position -308 TNFα gene promoter, DNA 
PCR product excision was performed using 
restriction enzymes NcoI which possessed 
5’-CCATGG-3’ recognition site. RFLP process 
was performed by adding 1 unit of restriction 
enzyme NcoI and 1 μL of the buffer solution 
NE buffer, 4 to 5 μL of PCR product and adding 
distilled water until 10 μL. All of them were 
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then incubated at 370C for 2 hours. The product 
of PCR-RFLP was electrophoresized resulting 
in homozygote -308A allele, which was cut 
into 2 bands with the size of 208 pb and 231 
pb and the homozygote allele-308G of which 
without any cutting; therefore, there was only 
one band appeared with a similar size to the size 
of the PCR product, i.e. 231 pb. While for the 
heterozygous samples, which brought  allele G 
and A, partial cutting occured and resulting in 3 
bands with sizes of 231 pb, 208 pb and 23 pb.
PCR-RFLP of -238 TNFα Gene
TNFα -238 genotype (rs361525) was 
analyzed with PCR-RFLP method using primers 
for PCR gene amplification, i.e. primer of 
ATC-TNFα−238G/A (rs361525 ), the primers 
were 5’ATCTGGAGGAAGCGGTAGTG-3’ 
and 5’-AGAAGACCCCC CTCGGAACC-3’. 
PCR reaction volume was 50 μL containing the 
following ingredients: 10 X buffer solution (5 
μL), 50 mM MgCl 2 (1.5 μL), 10 mM dNTPs 
(1 μL), 40 pmol/μL of ATC-1 primer (0.5 μL), 
40 pmol/μL of ATC-2 primer (0.5 μL), the 
isolated DNA samples (5 μL) and 1 unit of Taq 
polymerase enzyme. PCR cycle condition in 
TNFα gene fragment amplification was 940C 
for 30 sec, 580C for 30 sec and 720C for 1.5 min 
in 30 cycles.At the beginning of the reaction, 
additional denaturation time was given at 940C 
for 5 minutes and at the end of the reaction, there 
was additional elongation time at  720C  for 5 
minutes. Positive electrophoresis results of TNFα 
gene PCR was indicated by the presence of DNA 
band with the size of 150 pb. 
To determine whether the samples brought 
nucleotide A and/or nucleotide G at position -238 
TNFα gene promoter, DNA PCR product cutting 
was performed using restriction enzymes MspI 
which had 5’-CˇCGG-3’recognition site. The 
product of PCR-RFLP was electrophoresized 
resulting in homozygote allele -238A of which 
without any cutting; therefore, there was only 
one band appeared with a similar size to the size 
of the PCR product, 231 pb, and homozygote 
-238G allele was cut into 2 bands with the size 
of 130pb and 20pb. While for the heterozygous 
samples, which brought  allele G and A, partial 
cutting occured and resulting in 3 bands with 
sizes of 150 pb, 130 pb and 20 pb.
PCR-RFLP of +252 LTα Gene
LTα  +252 genotype (rs909253) was analyzed 
with PCR-RFLP method using primers for PCR 
gene amplification. The primers were HTB-1 
(5-CTG-ACT CTC CAT CTG TCA GT-3) and 
HTB-3 (5-TAC CAA TGA GGT GAG  CAG CA-
3). In the second reaction, the used primers were 
HTB-1 and HTB-2 (5-AGA CGT TCA GGT 
GGT GTC AT-3). Composition and condition of 
PCR amplification of LTα gene was performed 
using the same method for TNFα gene; however, 
there were some differences such as the use of 
HTB-1, HTB-2 and HTB-3 primers. Positive 
PCR result for LTα gene was indicated by the 
presence of DNA band with the size of 285 
pb. To determine whether the samples brought 
nucleotide A and/or nucleotide G at position 
+252 LTα gene promoter, DNA PCR product 
cutting was performed using restriction enzymes 
NcoI which carried 5’-CˇCATGG-3’ recognition 
site. For the homozygote allele +252A at which 
the cutting did not occur, there was only one 
band appeared with a similar size to the size of 
the PCR product, 285 pb and homozygote -238G 
allele was cut into 2 bands with sizes of 231pb 
and 54pb. While for the heterozygous samples, 
which brought allele G and A, partial cutting 
occured and resulting in 3 bands with sizes of 
285 pb, 231 pb and 54 pb.
Data Analysis 
The sample size of this study was calculated 
based on the study of Huang6, that found 
a correlation of gen alleles TNF-alpha 308 
between 19% of COPD patients and 2.4% of the 
control group with odds ratio of 11.1. We used 
the formula of case-control study for analytical 
unpaired comparative categorical data, applying 
the value of  α = 0.05 and β = 0.2 and resulting 
as much as 81 samples in each group; therefore, 
the total number of sample size was 162 subjects. 
Samples collecting procedure was conducted by 
consecutive sampling after obtaining approval 
from the Ethical Committee of Medical Faculty, 
University of North Sumatra.
Data analysis was performed using chi-
square test. We used chi-square test to determine 
the association between gene polymorphisms 
of TNFα as well as LTα and FEV1 values. The 
magnitude of risk of COPD in the TNFα gene 
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polymorphism and LTα was stated in odds ratios 
(OR). If the OR >1, we could conclude that 
TNFα or LTα gene polymorphism is a risk factor 
for COPD. The analysis was then continued to 
determine the magnitude of risk factor, expressed 
in 95% confidence interval (CI). Statistical 
findings was considered to be significant when 
p<0.05.
RESULTS
Of 227 people who had been examined, we 
obtained eligible sample size of 186 subjects 
after being matched with age and history of 
smoking. In details, there were 93 subjects in the 
case group and in the control group. The subjects 
for the case and control group was respectively 
93 male subjects (100%) with the eldest age 
range of 50-59 years (41.9% of the case group 
and 40.9% of the control group).
Analysis of TNFα -308 Gene Polymorphism
Table 2 shows the number of individuals 
who had allele G and A on TNFα -308 genotypes 
in the case and control group. There was a fewer 
number of allele G in the control group, i.e. 145 
subjects (78%); while in the case group with 
COPD, the number was 158 subjects (85%). The 






Allele A 28 (15.0) 41 (22.0)
Allele G 158 (85.0) 145 (78.0)
Total 186 (100.0) 186 (100.0)






Allele A 12 (6.5) 7 (3.8)
Allele G 174 (93.5) 179 (96.2)
Total 186 (100.0) 186 (100.0)






Allele A 130 (70.0) 126 (67.0)
Allele G 56 (30.0) 60 (33.0)
Total 186 (100.0) 186 (100.0)
Table 1. Data characteristics
Variables COPD non-COPD
Sex male, n (%) 93 (100) 93 (100)
Age (years), n (%)
 - 40-49 3 (5.4) 5 (3.2)
 - 50-59 38 (41.9) 39 (40.9)
 - 60-69 31 (31.2) 29 (33.3)
 - 70-79 15 (15.1) 14 (16.1)
 - 80-89 6 (6.5) 6 (6.5)
Smoking habit (IB), n (%)
 - Mild (IB<200) 0 (0.0) 0 (0.0)
 - Moderate (200<IB<600) 47 (50.6) 44 (47.3)
 - Heavy (IB>600) 46 (49.4) 49 (52.7)
Gold stage (%FEV1), n (%)
 - GOLD I (FEV1>80%) 1 (1.0)
 - GOLD II 
(50%<FEV1<80%) 26 (28.0)
 - GOLD III 
(305<FEV1<50% 47 (51.0)
 - GOLD IV (FEV1<30%) 19 (20.0)
IB=daily number of cigarettes x years
COPD case group had 28 subjects (15%) with 
allele A; while in the control group, there were 
41 subjects (22%). Based on the results, we found 
that there was less number of allele A in COPD 
cases compared to the control group.
Analysis of TNFα-238 Gene Polymorphism 
Table 3 shows the number of individuals 
who had allele G or A of TNFα-238 genotype in 
the case and control group. Allele G was found in 
179 subjects of the control group (96.2%); while 
in the COPD case group, we found 174 subjects 
(93.5%). Moreover, allele A was found in 12 
subjects of the COPD case group (6.5%) and in 
the control group, there were 7 subjects (3.8%).
Analysis of LTα +252 Gene Polymorphism
Table 4 shows the number of individuals 
who had allele G or A at LTα +252 genotype 
in the case and control group. There were 179 
subjects (96.2%) who had allele G in the control 
group; while in the COPD case group, the 
number was 174 subjects (93.5%). We found 12 
subjects (6.5%) with allele A in the COPD case 
and the number in the control group was equal 
to 7 subjects (3.8%).
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The association of TNFα Gene Polymorphism 
and LTα with COPD
Table 5 shows the -238G/A, -308G/A TNF 
gene and +252 A/G gene LTα polymorphism in 
COPD (case) and control group. For -238G/A, 
GA and AA genotypes, we found as many as 8 
subjects in the case group and 4 subjects in the 
control group. As for the GG genotype, there 
were as many as 85 subjects in the case group and 
89 subjects in the control group. Using statistical 
calculation, we obtained odds ratio 2.094 (95% 
CI 0.608 to 7.211), however, the difference 
was not considered statistically significant. For 
-308G/A genotypes polymorphism, GA and AA 
genotypes, we found as many as 18 subjects in 
the case group and 33 subjects in the control 
group. As for the GG genotype, there were 75 
subjects in the case group and 60 subjects in the 
control group. Statistical calculation revealed an 
odds ratio 0.436 (95% CI 0.224 to 0.850).
For polymorphism of +252 A/G, GA and 
GG genotypes, we found as many as 60 subjects 
in the case group and 55 subjects in the control 
group. While for AA genotype, there were as 
many as 33 subjects in the case group and 38 
subjects in the control group. We obtained an 
odds ratio  1.256 (95% CI 0.694 to 2.272).
DISCUSSION
Bronchial smooth muscle, cell hypertrophy, 
inflammatory process narrowing the peripheral 
airways and loss of elastic recoil may contribute 
to different extent in certain individuals. 
Susceptibility to these processes may have 
different genetic bases. A search for genes that 
increase susceptibility to airflow obstruction 
among smokers may have implications beyond 
the development of COPD.
Our study shows that -238 TNFα and +252 
LTα genes polymorphisms are not associated with 
the incidence of COPD; however, for the -308G/
A TNFα gene polymorphism, our results showed 
that -308A allele is more common in normal 
individuals and has been significantly proven 
to be a protective factor for the development of 
COPD. Based on the data analysis of our study, 
we conclude that polymorphism of -308 TNFα 
gene reduces the risk of COPD in smokers. 
COPD is also likely to occur less by 0.436 times 
in smokers who have a TNF-308A gene allele. 
However, these results are not in accordance 
with previous studies that have analyzed the 
association of TNFα gene polymorphisms with 
the incidence of COPD.8-10 The differences are 
likely due to different definition of the phenotype 
and race. Therefore, the risk of each different 
alleles is essential in different population as 
there may be different form of exposure and 
environmental factors. Moreover, differences 
in COPD phenotypes are more likely due to 
differences in mutations or gene polymorphisms. 
Data of some studies shows that the association 
of genes and gene analysis with the incidence 
of COPD in different populations should be 
studied further. The popula tion differences may 
be related to differences in specific genetic risk 
and environmental exposure. There are different 
results between our study and the study reported 
by Huang.5 It may be due to different position of 
the promoter segment.11 PCR products generated 
Table 5. Association of TNFa and LTa gene polymorphism with COPD
Genotypes COPD non-COPD OR (95% CI) p
-238 TNFa
 - GA - AA 8 4 2.09 (0.61-7.21) 0.24
 - GG 85 89
-308 TNFa
 - GA - AA 18 33 0.44 (0.22-0.85) 0.01
 - GG 75 60
+252 LTa
 - GA - GG 60 55 1.26 (0.69-2.27) 0.45
 - AA 33 38
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in our study were different in DNA base pairs 
from the PCR products which were examined by 
Huang. In our study, the result sized 231pb; while 
Huang obtained 345pb. TNFα promoter tip with 
1.5 κB length was  placed at the starting position 
of the gene transcription process (transcription 
start site/TSS) that served as a regulator of TNFα 
production.
It is possible that -308 TNFα gene 
polymorphism occurred in the population of our 
study leading to lower TNFα gene transcription 
process resulting in lower production of TNFα, 
which serves as inflammatory mediator. Another 
explanation is that the difference may be 
partially caused by different study populations 
and different criteria in selecting participants, in 
which we included COPD patients in our study; 
while Huang included patients with chronic 
bronchitis. Moreover, the number of sample size 
of our study is two-folds larger than the study 
conducted by Huang.5
Nevertheless, we still could not confirm 
the association of TNFα gene polymorphism 
at position -308 with COPD since the actual 
effect of the polymorphism in vivo has not been 
clearly demonstrated in our study. Further studies 
should be performed on the gene expression of 
-308A TNFα allele in  patients with COPD, on 
the serum levels of TNFα in patients with COPD 
and the sequences around the -308 position of 
TNFα gene  promoter as well as the identification 
of proteins associated with DNA sequences 
covering position. The studies are expected 
to provide useful information as an effort to 
characterize the gene promoter and its correlation 
to protective  factors on the incidence of COPD. 
A large number of genes and polymorphisms 
must first be identified and tested.
The limitation of this study includes the fact 
that there were only two genes analyzed in our 
study and this number was too small compared 
to all genes involved in the pathogenesis of 
COPD. Another limitation is that the sample 
in our study included all Indonesian ethnics 
(Bataknese, Javanese, etc) and it was not limited 
to a specific ethnic group; therefore, the effect 
of racial or ethnicity on the incidence of COPD 
is still obscure.
CONCLUSION
In summary, our results suggest that 
polymorphism of -238G/A TNFα and +252A/G 
LTα genes do not show any association with 
the incidence of COPD and polymorphism of 
-308G/A TNFα gene has been proven to be a 
protective factor for the development of COPD.
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